Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,234
datasets available to search
ShareScore release 0.9.0
Dataset results
2,234 results for “Paclitaxel”
Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC
ClinicalTrials.gov study NCT02501902. IPD Sharing: NO. Countries: 2. Publications: 1.
A Safety and Efficacy Study of BCD-021 With Paclitaxel and Carboplatin Compared to Avastin With Paclitaxel and Carboplatin in Non-Small Cell Lung Cancer
ClinicalTrials.gov study NCT01763645. IPD Sharing: Not stated. Countries: 4. Publications: 1.
A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
ClinicalTrials.gov study NCT02367781. IPD Sharing: Not stated. Countries: 8. Publications: 3.
Study of Cetuximab With and Without Weekly Paclitaxel for Patients With Previously Treated Advanced Urothelial Cancer
ClinicalTrials.gov study NCT00350025. IPD Sharing: Not stated. Countries: 1. Publications: 1.
LEVANT I, The Lutonix Paclitaxel-Coated Balloon for the Prevention of Femoropopliteal Restenosis
ClinicalTrials.gov study NCT00930813. IPD Sharing: Not stated. Countries: 2. Publications: 4.
Trial Exploring Afatinib (BIBW 2992) + Paclitaxel (Part A), Afatinib + Paclitaxel + Bevacizumab (Part B), Afatinib + Carboplatin (Part C) and Afatinib+ Paclitaxel +Carboplatin(Part D) in Patients With
ClinicalTrials.gov study NCT00809133. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer
ClinicalTrials.gov study NCT07018063. IPD Sharing: YES. Countries: 1. Publications: 12.
Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer
ClinicalTrials.gov study NCT00003644. IPD Sharing: Not stated. Countries: 2. Publications: 1.
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
ClinicalTrials.gov study NCT00110019. IPD Sharing: Not stated. Countries: 2. Publications: 1.
Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
ClinicalTrials.gov study NCT01468909. IPD Sharing: Not stated. Countries: 1. Publications: 2.
S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
ClinicalTrials.gov study NCT00946712. IPD Sharing: Not stated. Countries: 2. Publications: 2.
Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma
ClinicalTrials.gov study NCT00976573. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology
ClinicalTrials.gov study NCT00596830. IPD Sharing: Not stated. Countries: 26. Publications: 2.
Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer
ClinicalTrials.gov study NCT00031694. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)
ClinicalTrials.gov study NCT01964430. IPD Sharing: Not stated. Countries: 21. Publications: 6.
Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer
ClinicalTrials.gov study NCT00915018. IPD Sharing: Not stated. Countries: 35. Publications: 1.
Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)
ClinicalTrials.gov study NCT03377491. IPD Sharing: Not stated. Countries: 20. Publications: 9.
Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel
ClinicalTrials.gov study NCT02073487. IPD Sharing: NO. Countries: 1. Publications: 1.
Schedules of Nab-Paclitaxel in Metastatic Breast Cancer
ClinicalTrials.gov study NCT01746225. IPD Sharing: Not stated. Countries: 6. Publications: 5.
S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed b
ClinicalTrials.gov study NCT02562716. IPD Sharing: Not stated. Countries: 1. Publications: 3.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.